References
- Scallan E, Hoekstra RM, Angulo FJ et al. Foodborne illness acquired in the United States – major pathogens. Emerging Infect. Dis. 17(1), 7–15 (2011).
- Lopman BA, Hall AJ, Curns AT, Parashar UD. Increasing rates of gastroenteritis hospital discharges in US adults and the contribution of norovirus, 1996–2007. Clin. Infect. Dis. 52(4), 466–474 (2011).
- Patel MM, Widdowson MA, Glass RI et al. Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerging Infect. Dis. 14(8), 1224–1231 (2008).
- Hall AJ, Curns AT, McDonald LC, Parashar UD, Lopman BA. The roles of clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999–2007. Clin. Infect. Dis. 55(2), 216–223 (2012).
- Atmar RL, Bernstein DI, Harro CD et al. Norovirus vaccine against experimental human Norwalk Virus illness. N. Engl. J. Med. 365(23), 2178–2187 (2011).
- Glass RI, Parashar UD, Estes MK. Norovirus gastroenteritis. N. Engl. J. Med. 361(18), 1776–1785 (2009).
- Rydell GE, Kindberg E, Larson G, Svensson L. Susceptibility to winter vomiting disease: a sweet matter. Rev. Med. Virol. 21(6), 370–382 (2011).
- Czakó R, Atmar RL, Opekun AR et al. Serum hemagglutination inhibition activity correlates with protection from gastroenteritis in persons infected with Norwalk virus. Clin. Vaccine Immunol. 19(2), 284–287 (2012).
- Reeck A, Kavanagh O, Estes MK et al. Serological correlate of protection against norovirus-induced gastroenteritis. J. Infect. Dis. 202(8), 1212–1218 (2010).
- Johnson PC, Mathewson JJ, DuPont HL, Greenberg HB. Multiple-challenge study of host susceptibility to Norwalk gastroenteritis in US adults. J. Infect. Dis. 161(1), 18–21 (1990).
- Parrino TA, Schreiber DS, Trier JS, Kapikian AZ, Blacklow NR. Clinical immunity in acute gastroenteritis caused by Norwalk agent. N. Engl. J. Med. 297(2), 86–89 (1977).
- Estes MK, Ball JM, Guerrero RA et al. Norwalk virus vaccines: challenges and progress. J. Infect. Dis. 181(Suppl. 2), S367–S373 (2000).
- Ball JM, Graham DY, Opekun AR, Gilger MA, Guerrero RA, Estes MK. Recombinant Norwalk virus-like particles given orally to volunteers: Phase I study. Gastroenterology 117(1), 40–48 (1999).
- Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin. Immunol. 108(3), 241–247 (2003).
- El-Kamary SS, Pasetti MF, Mendelman PM et al. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J. Infect. Dis. 202(11), 1649–1658 (2010).
- Siebenga JJ, Vennema H, Renckens B et al. Epochal evolution of GGII.4 norovirus capsid proteins from 1995 to 2006. J. Virol. 81(18), 9932–9941 (2007).
- Lindesmith LC, Beltramello M, Donaldson EF et al. Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog. 8(5), e1002705 (2012).
- Lindesmith LC, Donaldson E, Leon J et al. Heterotypic humoral and cellular immune responses following Norwalk virus infection. J. Virol. 84(4), 1800–1815 (2010).
- Kitamoto N, Tanaka T, Natori K et al. Cross-reactivity among several recombinant calicivirus virus-like particles (VLPs) with monoclonal antibodies obtained from mice immunized orally with one type of VLP. J. Clin. Microbiol. 40(7), 2459–2465 (2002).
- Wyatt RG, Dolin R, Blacklow NR et al. Comparison of three agents of acute infectious nonbacterial gastroenteritis by cross-challenge in volunteers. J. Infect. Dis. 129(6), 709–714 (1974).
Website
- ClinicalTrials.gov. www.clinicaltrials.gov